Enhanced ADCC and NK cell activation of an anticarcinoma bispecific antibody by genetic insertion of a modified IL-15 cross-linker

Molecular Therapy

Volumn 24, Issue 7, 2016, Pages 1312-1322

  Schmohl, Joerg U ^a,b   Felices, Martin ^c   Taras, Elizabeth ^a   Miller, Jeff S ^c   Vallera, Daniel A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1615EPCAM BIKE; 1615EPCAM TRIKE; ANTINEOPLASTIC AGENT; CD56 ANTIGEN; CHROMIUM 51; EPITHELIAL CELL ADHESION MOLECULE; GAMMA INTERFERON; INTERLEUKIN 15; UNCLASSIFIED DRUG; BISPECIFIC ANTIBODY; CYTOKINE; HYBRID PROTEIN; PROTEIN BINDING;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD3+ T LYMPHOCYTE; CELL ENGINEERING; CELL KILLING; CELL SURVIVAL; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEGRANULATION; DNA SHUFFLING; GENE INSERTION; GENE SYNTHESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPHOCYTE PROLIFERATION; NATURAL KILLER T CELL; PROTEIN ASSEMBLY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN MODIFICATION; T LYMPHOCYTE ACTIVATION; TARGET CELL; BIOSYNTHESIS; CARCINOMA; CELL PROLIFERATION; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE ORDER; GENE VECTOR; GENETICS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NATURAL KILLER CELL; TUMOR CELL LINE;

ANTIBODIES, BISPECIFIC; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CARCINOMA; CELL DEGRANULATION; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOKINES; EPITHELIAL CELL ADHESION MOLECULE; GENE EXPRESSION; GENE ORDER; GENETIC VECTORS; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-15; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MUTAGENESIS, INSERTIONAL; PROTEIN BINDING; RECOMBINANT FUSION PROTEINS;

EID: 84982103393     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2016.88     Document Type: Article

References (57)

1. Gastl G, Spizzo G, Obrist P, Dünser M, and Mikuz G. (2000). Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet 356: 1981-1982.
2. Gutzmer R, Li, W, Sutterwala S, Lemos MP, Elizalde JI, Urtishak SL, et al. (2004). A tumor-Associated glycoprotein that blocks MHC class II-dependent antigen presentation by dendritic cells. J Immunol 173: 1023-1032.
3. Münz M, Kieu C, Mack B, Schmitt B, Zeidler R, and Gires O. (2004). The carcinomaassociated antigen EpCAM upregulates c-myc, and induces cell proliferation. Oncogene 23: 5748-5758.
4. Ensinger C, Kremser R, Prommegger R, Spizzo G, and Schmid KW. (2006). EpCAM overexpression in thyroid carcinomas: a histopathological study of 121 cases. J Immunother 29: 569-573.
5. Trzpis M, McLaughlin PM, de Leij LM, and Harmsen MC. (2007). Epithelial cell adhesion molecule: more than a carcinoma marker, and adhesion molecule. Am J Pathol 171: 386-395.
6. Munz M, Baeuerle PA, and Gires O. (2009). The emerging role of EpCAM in cancer, and stem cell signaling. Cancer Res 69: 5627-5629.
7. Gostner JM, Fong D, Wrulich OA, Lehne F, Zitt M, Hermann M, et al. (2011). Effects of EpCAM overexpression on human breast cancer cell lines. BMC Cancer 11: 45.
8. Yamashita T, Budhu A, Forgues M, and Wang XW. (2007). Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. Cancer Res 67: 10831-10839.
9. Ströhlein MA, Lordick F, Rüttinger D, Grützner KU, Schemanski OC, Jäger M, et al. (2011). Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon gastric or pancreatic cancer: an open-label multicenter phase I/II trial. Onkologie 34: 101-108.
10. Bargou R, Leo E, Zugmaier G, Klinger M, Goebeler M, Knop S, et al. (2008). Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321: 974-977.
11. Barrett DM, Teachey DT, and Grupp SA. (2014). Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr 26: 43-49.
12. Schmohl JU, Gleason MK, Dougherty PR, Miller JS, and Vallera DA. (2015). Heterodimeric bispecific single chain variable fragments. (scFv) killer engagers. (BiKEs) enhance NK-cell activity against CD133+ colorectal cancer cells. Target Oncol. (epub ahead of print). doi 10.1007/s11523-015-0391-8
13. Vallera DA, Zhang B, Gleason MK, Oh S, Weiner LM, Kaufman DS, et al. (2013). Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM, and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells. Cancer Biother Radiopharm 28: 274-282.
14. Papadakis KA, Prehn JL, Landers C, Han Q, Luo X, Cha SC, et al. (2004). TL1A synergizes with IL-12, and IL-18 to enhance IFN-gamma production in human T cells, and NK cells. J Immunol 172: 7002-7007.
15. Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, et al. (2014). CD16xCD33 bispecific killer cell engager. (BiKE) activates NK cells against primary MDS, and MDSC CD33+ targets. Blood 123: 3016-3026.
16. Alderson KL, and Sondel PM. (2011). Clinical cancer therapy by NK cells via antibodydependent cell-mediated cytotoxicity. J Biomed Biotechnol 2011: 379123.
17. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, et al. (1994). Interleukin. (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med 180: 1395-1403.
18. Fehniger TA, Shah MH, Turner MJ, VanDeusen JB, Whitman SP, Cooper MA, et al. (1999). Differential cytokine, and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response. J Immunol 162: 4511-4520.
19. Cooper MA, Fehniger TA, Turner SC, Chen KS, Ghaheri BA, Ghayur T, et al. (2001). Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood 97: 3146-3151.
20. Lanier LL, Le AM, Civin CI, Loken MR, and Phillips JH. (1986). The relationship of CD16. (Leu-11), and Leu-19. (NKH-1) antigen expression on human peripheral blood NK cells, and cytotoxic T lymphocytes. J Immunol 136: 4480-4486.
21. Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA, and Ritz J. (1990). Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med 171: 1509-1526.
22. Finney HM, Akbar AN, and Lawson AD. (2004). Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol 172: 104-113.
23. Imai C, Mihara K, Andreansky M, Nicholson IC, Pui CH, Geiger TL, et al. (2004). Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18: 676-684.
24. Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, et al. (2013). Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 368: 1509-1518.
25. Pinz K, Liu H, Golightly M, Jares A, Lan F, Zieve GW, et al. (2016). Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor. (CAR)-engineered T cells. Leukemia 30: 701-707.
26. Osenga KL, Hank JA, Albertini MR, Gan J, Sternberg AG, Eickhoff J et al.; Children?s Oncology Group. (2006). A phase I clinical trial of the hu14.18-IL2. (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma, and melanoma: a study of the Children?s Oncology Group. Clin Cancer Res 12: 1750-1759.
27. King DM, Albertini MR, Schalch H, Hank JA, Gan J, Surfus J, et al. (2004). Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients. J Clin Oncol 22: 4463-4473.
28. Ko YJ, Bubley GJ, Weber R, Redfern C, Gold DP, Finke L, et al. (2004). Safety pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066. (huKS-IL2): results of a phase I trial in patients with prostate cancer. J Immunother 27: 232-239.
29. Connor JP, Felder M, Hank J, Harter J, Gan J, Gillies SD, et al. (2004). Ex vivo evaluation of anti-EpCAM immunocytokine huKS-IL2 in ovarian cancer. J Immunother 27: 211-219.
30. Yamamoto T, Yanagimoto H, Satoi S, Toyokawa H, Hirooka S, Yamaki S, et al. (2012). Circulating CD4+CD25+ regulatory T cells in patients with pancreatic cancer. Pancreas 41: 409-415.
31. Munger W, DeJoy SQ, Jeyaseelan R Sr, Torley LW, Grabstein KH, Eisenmann J, et al. (1995). Studies evaluating the antitumor activity, and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2. Cell Immunol 165: 289-293.
32. Ranson T, Vosshenrich CA, Corcuff E, Richard O, Müller W, and Di Santo JP. (2003). IL-15 is an essential mediator of peripheral NK-cell homeostasis. Blood 101: 4887-4893.
33. Huntington ND, Legrand N, Alves NL, Jaron B, Weijer K, Plet A, et al. (2009). IL-15 trans-presentation promotes human NK cell development, and differentiation in vivo. J Exp Med 206: 25-34.
34. Waldmann TA. (2014). Interleukin-15 in the treatment of cancer. Expert Rev Clin Immunol 10: 1689-1701.
35. Basak GW, Zapala L, Wysocki PJ, Mackiewicz A, Jakóbisiak M, and Lasek W. (2008). Interleukin 15 augments antitumor activity of cytokine gene-modified melanoma cell vaccines in a murine model. Oncol Rep 19: 1173-1179.
36. Vallera DA, Felices M, McElmurry RT, McCullar V, Zhou X, Schmohl J, et al. (2016). IL-15 trispecific killer engagers. (TriKEs) make natural killer cells specific to CD33+ targets while also inducing in vivo expansion, and enhanced function. Clin Cancer Res. (epub ahead of print). doi 10.1158/1078-0432.CCR-15-2710
37. Conlon KC, Lugli E, Welles HC, Rosenberg SA, Fojo AT, Morris JC, et al. (2015). Redistribution hyperproliferation activation of natural killer cells, and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J Clin Oncol 33: 74-82.
38. Hodge DL, Yang J, Buschman MD, Schaughency PM, Dang H, Bere W, et al. (2009). Interleukin-15 enhances proteasomal degradation of bid in normal lymphocytes: implications for large granular lymphocyte leukemias. Cancer Res 69: 3986-3994.
39. Fehniger TA, Suzuki K, VanDeusen JB, Cooper MA, Freud AG, and Caligiuri MA. (2001). Fatal leukemia in interleukin-15 transgenic mice. Blood Cells Mol Dis 27: 223-230.
40. Khawam K, Giron-Michel J, Gu, Y, Perier A, Giuliani M, Caignard A, et al. (2009). Human renal cancer cells express a novel membrane-bound interleukin-15 that induces in response to the soluble interleukin-15 receptor alpha chain epithelial-Tomesenchymal transition. Cancer Res 69: 1561-1569.
41. Kuniyasu H, Ohmori H, Sasaki T, Sasahira T, Yoshida K, Kitadai Y, et al. (2003). Production of interleukin 15 by human colon cancer cells is associated with induction of mucosal hyperplasia angiogenesis, and metastasis. Clin Cancer Res 9: 4802-4810.
42. Kuniyasu H, Oue N, Nakae D, Tsutsumi M, Denda A, Tsujiuchi T, et al. (2001). Interleukin-15 expression is associated with malignant potential in colon cancer cells. Pathobiology 69: 86-95.
43. Trentin L, Cerutti A, Zambello R, Sancretta R, Tassinari C, Facco M, et al. (1996). Interleukin-15 promotes the growth of leukemic cells of patients with B-cell chronic lymphoproliferative disorders. Blood 87: 3327-3335.
44. Zambello R, Facco M, Trentin L, Sancetta R, Tassinari C, Perin A, et al. (1997). Interleukin-15 triggers the proliferation, and cytotoxicity of granular lymphocytes in patients with lymphoproliferative disease of granular lymphocytes. Blood 89: 201-211.
45. Baeuerle PA, and Gires O. (2007). EpCAM. (CD326) finding its role in cancer. Br J Cancer 96: 417-423.
46. Spizzo G, Went P, Dirnhofer S, Obrist P, Simon R, Spichtin H, et al. (2004). High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat 86: 207-213.
47. Seimetz D, Lindhofer H, and Bokemeyer C. (2010). Development, and approval of the trifunctional antibody catumaxomab. (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat Rev 36: 458-467.
48. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, et al. (2010). The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial. Int J Cancer 127: 2209-2221.
49. Petrelli F, Borgonovo K, Lonati V, Elia S, and Barni S. (2013). Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer. Target Oncol 8: 291-294.
50. Bezan A, Hohla F, Meissnitzer T, and Greil R. (2013). Systemic effect of catumaxomab in a patient with metastasized colorectal cancer: a case report. BMC Cancer 13: 618.
51. Gleason MK, Verneris MR, Todhunter DA, Zhang B, McCullar V, Zhou SX, et al. (2012). Bispecific, and trispecific killer cell engagers directly activate human NK cells through CD16 signaling, and induce cytotoxicity, and cytokine production. Mol Cancer Ther 11: 2674-2684.
52. Stein C, Kellner C, Kügler M, Reiff N, Mentz K, Schwenkert M, et al. (2010). Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. Br J Haematol 148: 879-889.
53. Singer H, Kellner C, Lanig H, Aigner M, Stockmeyer B, Oduncu F, et al. (2010). Effective elimination of acute myeloid leukemic cells by recombinant bispecific antibody derivatives directed against CD33, and CD16. J Immunother 33: 599-608.
54. McCall AM, Adams GP, Amoroso AR, Nielsen UB, Zhang L, Horak E, et al. (1999). Isolation, and characterization of an anti-CD16 single-chain Fv fragment, and construction of an anti-HER2/neu/anti-CD16 bispecific scFv that triggers CD16-dependent tumor cytolysis. Mol Immunol 36: 433-445.
55. Zhu X, Marcus WD, Xu W, Lee HI, Han K, Egan JO, et al. (2009). Novel human interleukin-15 agonists. J Immunol 183: 3598-3607.
56. Fogh J, Fogh JM, and Orfeo T. (1977). One hundred, and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 59: 221-226.
57. Klein E, Klein G, Nadkarni JS, Nadkarni JJ, Wigzell H, and Clifford P. (1968). Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo, and in derived culture lines. Cancer Res 28: 1300-1310.